.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory

EP. 1: Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.

December 24th 2024

Panelists discuss how current treatment approaches for transplant-ineligible newly diagnosed multiple myeloma patients are evolving with the addition of anti-CD38 therapies to standard VRd backbone, while examining unmet needs and the role of MRD negativity as an endpoint through recent trial data including CEPHEUS.